Cipla, has announced a massive reduction of up to 76 per cent in its cancer drug prices after the Indian government recently lifted a patent license.
Following the move,
- The price of Cipla’s generic kidney cancer drug, Sorafenib, will be available at Rs 6,840 a month from the earlier Rs 27,950.
- The lung cancer drug Gestinib price has been cut down by 60 per cent to just over Rs 4000, instead of earlier Rs 10,200.
- Temozolamide, a very effective brain tumour treatment drug has come down to Rs 5000 from the original Rs 20,250.